TabsDetailsBasic DetailsDate Posted: Monday, September 16, 2019Status: CompleteMedical Product: Copaxone, Gilenya, Glatopa, glatiramerHealth Outcome(s): multiple sclerosis relapseDescription: The goals of this request were to 1) estimate the rate of multiple sclerosis (MS) relapses among Copaxone, Glatopa, Gilenya, and glatiramer users and 2) compare MS relapse algorithms in the Sentinel Distributed Database (SDD). Data from September 21, 2010 to January 31, 2018 from 17 Data Partners contributing to the SDD were included in this report. This request was distributed on June 26, 2018. Read More Deliverables (1)Sentinel Modular Program Report: Multiple Sclerosis Relapses among Copaxone, Glatopa, Gilenya, and Glatiramer UsersAdditional InformationAdditional DetailsFDA Center: CDERTime Period: September 21, 2010 - January 31, 2018Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: Individuals 18 to 64 years of ageData Sources: Sentinel Distributed Database (SDD)
